Akebia Therapeutics, Inc. cash flow to debt ratio of 31.43% indicates that the company generates enough cash to cover its debts. This level indicates strong financial health.

Akebia Therapeutics, Inc.'s free cash flow has increased -267.09% from $-40.69M last year to $67.99M, signaling increasing performance

Akebia Therapeutics, Inc.'s debt to equity ratio is 0.46, which means that the company's assets are healthy financed, signaling financial stability. READ MORE: A ratio under 0.60 means the company finances its assets with own equity, signaling financial stability and good management.

Akebia Therapeutics, Inc.'s debt has increased relative to shareholder equity from -3.84 last year to 0.46 today, signaling weakened financials

Akebia Therapeutics, Inc. has a net debt to EBITDA ratio of 1.45x, which is below the 3.00x threshold, indicating healthy leverage and financial stability

Akebia Therapeutics, Inc.'s interest coverage ratio is 0.45, which means that the company struggles to meet interest obligations, signaling financial risk.

Akebia Therapeutics, Inc.'s profit margin has increased (-79.63%) in the last year from -43.33% to -8.83%, signaling increasing performance

Akebia Therapeutics, Inc.'s short-term assets of $184.84M exceed its short-term liabilities of $162.94M

Akebia Therapeutics, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Akebia Therapeutics, Inc.'s return on equity of -62.72%, is lower than 15.00%, indicating bad performance

Akebia Therapeutics, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Akebia Therapeutics, Inc. had positive net income in only 0.00 out of 5 years, indicating unstable earnings

Akebia Therapeutics, Inc. has positive free cash flow, indicating the company generates cash after capital expenditures

Akebia Therapeutics, Inc. has a free cash flow yield of 18.10%, which is above the 2.00% threshold, indicating strong cash generation relative to market value

Akebia Therapeutics, Inc.'s yearly earnings has increased -92.30% since last year from $-69.41M to $-5.34M, signaling increasing performance

Akebia Therapeutics, Inc.'s yearly revenue has increased 47.46% since last year from $160.18M to $236.20M, signaling increasing performance

ROIC 2.63% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Akebia Therapeutics, Inc.'s 3-year revenue CAGR of -6.88% is negative, indicating declining revenue over the past 3 years

Akebia Therapeutics, Inc. had revenue growth in only 2.00 out of 5 years, indicating inconsistent revenue performance

Akebia Therapeutics, Inc. had positive ROE in only 0.00 out of 5 years, indicating inconsistent returns on equity

Akebia Therapeutics, Inc. has insufficient data to evaluate this check.

Akebia Therapeutics, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Akebia Therapeutics, Inc. is overvalued relative to its fair value price of 0.46 based on EBITDA multiple model

Akebia Therapeutics, Inc. has an EV/EBITDA ratio of 18.73x, which is below the 20.00x threshold, indicating reasonable valuation relative to its operating earnings

Akebia Therapeutics, Inc. is overvalued relative to its fair value price of -1.70 based on Earnings Fair Value model

Akebia Therapeutics, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Akebia Therapeutics, Inc. has a price-to-book ratio of 13.66x, which exceeds the 5.00x threshold, indicating the stock may be overvalued relative to its book value

Akebia Therapeutics, Inc. has a price-to-sales ratio of 1.61x, which is below the 8.00x threshold, indicating reasonable valuation relative to its revenue